This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEW YORK (
Clinical Data(CLDA) was the biggest gainer among small-caps Monday afternoon, its shares soaring 55% to $23.30, after U.S. regulators approved its major depressive disorder treatment Viibryd. The biotech company said the drug would be available in U.S. pharmacies by the second quarter. Over 9 million shares changed hands.
Genoptix(GXDX) jumped 26% to $24.83 on heavy volumes after Swiss pharma giant
Novartis(NVS) said it was acquiring the diagnostics laboratory for $470 million or $25 per share in an all cash deal.
Rexahn Pharmaceuticals(RNN) shot up 20% to $1.57 after Israel-based
Teva Pharmaceuticals(TEVA) said it had acquired a 6% stake in the company at $1.69 per share.
Several solar stocks were shining on the bourses after Goldman Sachs added
First Solar(FSLR - Get Report) to its conviction list. Shares of
LDK Solar(LDK) were surging 10.5% to $14.53.
Trina Solar(TSL - Get Report) and
ReneSola(SOL - Get Report) were also up sharply.
Depomed(DEPO) were recovering Monday after plunging last week, rising 7.2% to $6.23. The stock took a hit last week after it said that
Abbot Laboratories(ABT) was reluctant to market its pain reliever drug.
Level 3 Communications(LVLT),
Dot Hill Systems(HILL),
Pluristem Therapeutics(PSTI) and
ATP Oil and Gas(ATPG) were among the other major gainers on Monday.
-- Written by Shanthi Bharatwaj in New York
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to: